Assistant Professor in the Division of Rheumatology and Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago Medical Center
Contributing author, rheumatology
Pankti Reid, MD, MPH, is an Assistant Professor in the Division of Rheumatology and Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago Medical Center. She completed her rheumatology fellowship as well as her Clinical Pharmacology and Pharmacogenomics Fellowship at the University of Chicago.
Her primary focus within rheumatology is judicious repurposing of rheumatology medications for therapy of immune-related adverse events (irAEs) or off-target toxicities of cancer immunotherapy. She has established a robust irAE clinical infrastructure that includes an irAE Clinic, an electronic referral system and an interdisciplinary irAE Clinical Consortium. She is currently developing an irAE curriculum for internal medicine residents, and oncology and rheumatology fellows. She is a member of a national, multi-institutional consortium of rheumatologists collaborating to improve evaluation and management of rheumatic irAEs.
During the COVID-19 pandemic, she has served as the principal investigator for two investigator-initiated clinical trials that study the judicious dosing of a well-known rheumatic drug, tocilizumab, for COVID-19 hyperinflammation.
In addition to her work being recognized at national rheumatology and oncology conferences, she has authored multiple book chapters and numerous peer-reviewed publications in prestigious journals like the Journal of the American Medical Association and the Journal of Immunotherapy for Cancer.
You can follow her on Twitter at @ReidMDMPH